Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03838926
PHASE1

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Sponsor: Vanda Pharmaceuticals

View on ClinicalTrials.gov

Summary

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

42

Start Date

2018-09-27

Completion Date

2027-12

Last Updated

2026-03-16

Healthy Volunteers

No

Interventions

DRUG

Trichostatin A

Intravenous Infusion

Locations (11)

Vanda Investigational Site

Washington D.C., District of Columbia, United States

Vanda Investigational Site

Lafayette, Indiana, United States

Vanda Investigational Site

Hackensack, New Jersey, United States

Vanda Investigational Site

Seattle, Washington, United States

Vanda Investigational Site

Biała Podlaska, Poland

Vanda Investigational Site

Katowice, Poland

Vanda Investigational Site

Krakow, Poland

Vanda Investigational Site

Opole, Poland

Vanda Investigational Site

Skorzewo, Poland

Vanda Investigational Site

Warsaw, Poland

Vanda Investigational Site

Wroclaw, Poland